Gossamer Bio
GOSS
71 hedge funds and large institutions have $776M invested in Gossamer Bio in 2019 Q1 according to their latest regulatory filings, with 71 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
54.49% more ownership
Funds ownership: 0% → 54.49% (+54%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
+$145M |
| 2 |
HIM
Hillhouse Investment Management
Grand Cayman,
Cayman Islands
|
+$104M |
| 3 |
Capital International Investors
Los Angeles,
California
|
+$68.3M |
| 4 |
BC
Boxer Capital
San Diego,
California
|
+$39.1M |
| 5 |
AG
Artal Group
Luxembourg
|
+$34.6M |
Top Sellers
GOSS Hedge Fund Activity: Q1 2019 in Review
71 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Gossamer Bio (GOSS) for Q1 2019, worth a combined $776M.
Buyers outnumbered sellers: 71 funds opened new GOSS positions and 0 closed out — a net gain of 71 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Omega Fund Management, opening a new position worth an estimated $145M.
- 71 institutional investors held Gossamer Bio (GOSS) as of Q1 2019, up from 0 in Q4 2018.
- Funds reported $776M of Gossamer Bio stock for Q1 2019.
- 71 funds opened new Gossamer Bio positions in Q1 2019 and 0 closed out, a net change of +71 holders.
- The largest Gossamer Bio buyer in Q1 2019 was Omega Fund Management, an estimated $145M added.
Based on aggregated 13F filings for Q1 2019.